| Clone | IHC672 |
| Source | Mouse Monoclonal |
| Positive Control | Testes, Melanoma, Xp11.2 Translocation Renal Cell Carcinoma |
| Dilution Range | 1:200 |
Transcription Factor E3 (TFE3) is a transcription factor that binds to the MUE3-type E-box sequences involved in TGF-β signalling. Anti-TFE3 staining is the most sensitive and specific indicator of Xp11 translocation renal cell carcinomas. Since alveolar soft part sarcoma (ASPS) is characterized by a specific chromosomal rearrangement resulting in a chimeric transcription factor (ASPSCR1-TFE3), this TFE3 IVD antibody is also a useful diagnostic tool for recognizing ASPS.
Mycoplasma is the smallest and simplest prokaryotic organism. There is a risk of mycoplasma contamination during cell culture, and mycoplasma contamination of cells has become a common problem worldwide.
Mycoplasma contamination may seriously affect the state of cells, change the gene expression and metabolic characteristics of cells, lead to slow cell growth, abnormal differentiation and death, and seriously affect cell function.
Bacteria, yeast or mold contamination in cell culture can be seen under an optical microscope, but mycoplasma contamination is usually not visible under an optical microscope and must be detected by specific detection methods.
Common methods for detecting mycoplasma contamination include mycoplasma isolation and culture, special biochemical tests such as ELISA and luminescence, and DNA fluorescent staining detection. Among the above detection methods, most of the operation steps are relatively cumbersome, the sensitivity is not high, the mycoplasma types cannot be distinguished, special instruments are required, or the time required is long. The qPCR method is relatively simple and convenient to operate, and the results can be obtained in 2 hours.
• Provide results in less than 2 hours.
Good negative and positive controls.
• No live mycoplasma required: The MycoSEQ Mycoplasma Detection Kit does not contain any live mycoplasma and does not require the use of live mycoplasma for validation
• Can be used with gDNA, inactivated mycoplasma, or live mycoplasma
• Can be used as an alternative to the standard 28-day culture test
• Can be used in conjunction with culture-based methods to provide preliminary results while awaiting the 28-day test results
The MycoSEQ Plus Mycoplasma Detection Kit is part of an integrated workflow for adventitious drug, impurity, and contaminant detection during biopharmaceutical manufacturing. The entire workflow includes the sample preparation kit, which provides a manual sample preparation method, which together with the qPCR analysis can provide results in 2 hours. (Please note that complex matrices may require additional upfront processing steps as described in the various available protocols.)
• Mycoplasma qPCR MIX, store at -15°C to -25°C, store at 2°C to 8°C after first use, protected from light.
• Mycoplasma Positive Control, -15°C to -25°C.
• Mycoplasma Negative Control, store at -15°C to -25°C, store at 2°C to 8°C after first use.
Note: Price not include shipment & duty, contact us to get full quote.
DuckyBio’s Mycoplasma PCR Detection Kit is a TaqMan™-based quantitative PCR (qPCR) kit for detecting mycoplasma contamination in biological materials such as cultured cells. Designed and tested using criteria often applied toward rapid mycoplasma detection in biotherapeutic manufacturing cell culture lot release, the MycoSEQ Plus kit enables results that meet or exceed guidance on sensitivity and specificity expectations as described in European Pharmacopoeia (E.P. 2.6.7, 2007), US Pharmacopoeia (US63) and Japanese Pharmacopoeia. When used with a suitable sample preparation method, the MycoSEQ Plus kit can detect less than 5 CFU/mL.
| Clone | IHC411 |
| Source | Rabbit Monoclonal |
| Positive Control | Tonsil, Lung Adenocarcinoma |
| Dilution Range | 1:200 |
Programmed Death-Ligand 1 (PD-L1), also known as CD274 or B7 Homolog 1 (B7-H1), is a transmembrane protein involved in suppressing the immune system and rendering tumor cells resistant to CD8 T cell-mediated lysis through binding of the Programmed Death-1 (PD-1) receptor. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. In renal cell carcinoma, upregulation of PD-L1 has been linked to increased tumor aggressiveness and risk of death, and, in ovarian cancer, higher expression of this protein has lead to significantly poorer prognosis. PD-L1 has also been linked to systemic lupus erythematosus and cutaneous melanoma. When considered in adjunct with CD8 tumor-infiltrating lymphocyte density, expression levels of PD-L1 may be a useful predictor of multiple cancer types, including stage III non-small cell lung cancer, hormone receptor negative breast cancer, and sentinel lymph node melanoma.